Allarity Therapeutics (NASDAQ:ALLR) Stock Price Down 0.7% – Here’s What Happened

Posted by Brenda Bartman on Sep 6th, 2026

Allarity Therapeutics, Inc. (NASDAQ:ALLR – Get Free Report)’s stock price dropped 0.7% during mid-day trading on Friday . The stock traded as low as $1.40 and last traded at $1.42. 54,487 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 79,940 shares. The stock had previously closed at $1.43.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ALLR. Ascendiant Capital Markets increased their price objective on Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a report on Monday, June 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $10.25.

Check Out Our Latest Analysis on ALLR

Allarity Therapeutics Stock Performance

The firm has a 50-day moving average price of $1.30 and a 200-day moving average price of $1.31. The stock has a market cap of $22.59 million, a PE ratio of -1.82 and a beta of 0.56.

Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.04. As a group, sell-side analysts anticipate that Allarity Therapeutics, Inc. will post -0.92 EPS for the current fiscal year.

Hedge Funds Weigh In On Allarity Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in shares of Allarity Therapeutics in the 4th quarter worth $36,000. DRW Securities LLC purchased a new stake in shares of Allarity Therapeutics during the 4th quarter valued at about $133,000. Renaissance Technologies LLC boosted its holdings in Allarity Therapeutics by 274.1% in the fourth quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after purchasing an additional 181,426 shares during the last quarter. Citadel Advisors LLC bought a new stake in Allarity Therapeutics in the 3rd quarter worth approximately $149,000. Finally, Private Advisor Group LLC bought a new stake in Allarity Therapeutics in the 3rd quarter worth approximately $441,000. 11.53% of the stock is owned by institutional investors.

Allarity Therapeutics Company Profile

(Get Free Report)

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.